about
Drug treatment for spinal muscular atrophy types II and IIIDrug treatment for spinal muscular atrophy types II and IIIDrug treatment for spinal muscular atrophy types II and IIIGranulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosisNerve growth factor for Bell's palsy: A meta-analysis.Impaired expression of insulin-like growth factor-1 system in skeletal muscle of amyotrophic lateral sclerosis patients.Microwave-assisted synthesis of 4-chloro-N-(naphthalen-1-ylmethyl)-5-(3-(piperazin-1-yl)phenoxy)thiophene-2-sulfonamide (B-355252): a new potentiator of Nerve Growth Factor (NGF)-induced neurite outgrowthGene therapy for the treatment of sensory neuropathy.Neurotrophic factors and amyotrophic lateral sclerosis.Olesoxime protects embryonic cortical neurons from camptothecin intoxication by a mechanism distinct from BDNF.Synergistic effects of GDNF and VEGF on lifespan and disease progression in a familial ALS rat modelEnhancing and regulating neurite outgrowth.Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.Prolonged regulatable expression of EPO from an HSV vector using the LAP2 promoter elementLow-Affinity Neurotrophin Receptor p75 Promotes the Transduction of Targeted Lentiviral Vectors to Cholinergic Neurons of Rat Basal Forebrain.2-decenoic acid ethyl ester, a compound that elicits neurotrophin-like intracellular signals, facilitating functional recovery from cerebral infarction in mice.Protective effect of HSV-mediated gene transfer of nerve growth factor in pyridoxine neuropathy demonstrates functional activity of trkA receptors in large sensory neurons of adult animals.Thrombopoietin is ineffective in a mouse model of motor neuron disease
P2860
Q24200270-C469A737-F447-42C0-A6A5-277A00CA741BQ24234414-E1E1BF93-D0C7-4C14-8B11-7C967255ECC2Q24241759-D3E0D5E8-0FE6-4E74-AAC9-1A08D921E90CQ24655277-BAF94D05-3C23-4D3D-A274-2615AC3A618DQ34795795-547AF095-CC53-4DC5-9A0F-39ECFEBB93A4Q35837412-F84FCF28-8792-47E5-8571-FC229BCBC9D7Q36220470-18C5D9C0-FE12-48F9-AE10-35D77EB4B9D7Q36446943-C31A4012-1208-458F-8DCB-DD4B8529124DQ36565607-A98B27A5-9267-4B39-9004-4881B3D7C77FQ36757014-B279DB28-7BCD-4E7B-9D94-2728685A59DCQ37073110-C652CA75-90E1-43E8-81B0-CE025E4B0C0CQ37146142-E05068D1-1F7D-4F8C-973E-896C1D4276B4Q37318152-9D4E3C40-7BC7-4787-83D5-3849F53E00E9Q39442049-334BE66A-7B30-47DD-BCF2-0FE8AB5BC4B4Q41585067-CD193BA7-D874-4A35-AD42-D442C3F57E9AQ41892275-B1C59F8F-DD3E-4BC4-B70C-F843FEC66C19Q44326167-42F25E5B-413D-4B0E-A67B-F5CB63ACEDB0Q58125301-C475FBF5-484A-489F-8D51-69232BDB3148
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Neurotrophic factor therapy--prospects and problems.
@ast
Neurotrophic factor therapy--prospects and problems.
@en
Neurotrophic factor therapy--prospects and problems.
@nl
type
label
Neurotrophic factor therapy--prospects and problems.
@ast
Neurotrophic factor therapy--prospects and problems.
@en
Neurotrophic factor therapy--prospects and problems.
@nl
prefLabel
Neurotrophic factor therapy--prospects and problems.
@ast
Neurotrophic factor therapy--prospects and problems.
@en
Neurotrophic factor therapy--prospects and problems.
@nl
P2860
P356
P1476
Neurotrophic factor therapy--prospects and problems.
@en
P2093
P2860
P304
P356
10.1515/CCLM.2001.055
P577
2001-04-01T00:00:00Z